Abstract
The stem cell field has grown very rapidly over the past decade and continues to be one of the most exciting areas of biomedical research. It is now known that stem cells are potential for improvement of pathological condition in many diseased organs, which is not possible in case of pharmaceutical drugs. Adult stem cells are most familiar for autologous and allogenic applications in different clinical indications. With the ability to produce an unlimited number of many kinds of human cells, the pluripotent stem cells have entered in the forefront of the regenerative medicine. However, several challenges must be overcome before clinical applications become a reality. More specifically, the challenges for the coming years are to extend multidisciplinary and multi-sector collaboration aimed at large-scale production of high-quality stem cell products, development of robust methods for characterization of cells, and assessment of therapeutic value. In this report, I have discussed about certain biological issues that might involve in determining the therapeutic potential and obtaining regulatory approval for the stem cell-based products. Other major aspect of this report has been manufacturing of cells and challenges for large-scale production.
Keywords
Abbreviations
- ALF:
-
Acute liver failure
- CHD:
-
Chronic heart disease
- CLI:
-
Chronic liver injury
- CPCs:
-
Cardiovascular progenitor cells
- ESCs:
-
Embryonic stem cells
- HSPCs:
-
Hematopoietic stem and progenitor cells
- iPSCs:
-
Induced pluripotent stem cells
- LVEF:
-
Left ventricular ejection fraction
- MI:
-
Myocardial infarction
- MSCs:
-
Mesenchymal stem cells
- RPE:
-
Retinal pigment epithelium
- SCI:
-
Spinal cord injury
References
Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008;3:1–5.
Tavassoli M, Crosby WH. Transplantation of marrow to extramedullary sites. Science. 1968;161:54–6.
Clinical Trials Website of the United States Sponsored by the National Institutes of Health. http://clinicaltrials.gov.
Chapel A, Bertho JM, Bensidhoum M, et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med. 2003;5:1028–38.
Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–22.
Hsieh JY, Wang HW, Chang SJ, et al. Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One. 2013;8:1–11.
Linero I, Chaparro O. Paracrine effect of mesenchymal stem cells derived from human adipose tissue in bone regeneration. PLoS One. 2014;9:1–12.
Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2:141–50.
Li N, Lu X, Zhao X, et al. Endothelial nitric oxide synthase promotes bone marrow stromal cell migration to the ischemic myocardium via upregulation of stromal cell-derived factor-1 alpha. Stem Cells. 2009;27:961–70.
Reffelmann T, Konemann S, Kloner RA. Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. J Am Coll Cardiol. 2009;53:305–8.
Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167:989–97.
Jeevanantham V, Butler M, Saad A, et al. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation. 2012;126:551–68.
Martin G, Sutton J, Sharpe N. Left ventricular remodeling after myocardial infarction pathophysiology and therapy. Circulation. 2000;101:2981–8.
Frank T, Henning WZ. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol. 2014;60:1090–6.
El-Ansary M, Mogawer S, Abdel-Aziz I, et al. Phase I trial: mesenchymal stem cells transplantation in end stage liver disease. J Am Sci. 2010;6:135–44.
Zhang Z, Lin H, Shi M, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 2012;27:112–20.
Akihiro S, Yoshio S, Takuya K, et al. Adipose tissue-derived stem cells as a regenerative therapy for a mouse steatohepatitis-induced cirrhosis model. Hepatology. 2013;58:1133–42.
Chiung-Kuei H, Soo OL, Kuo-Pao L, et al. Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. Hepatology. 2013;57:1550–63.
di Bonzo LV, Ferrero I, Cravanzola C, et al. Human MSCs as a two-edge sword in hepatic regenerative medicine: engraftment and hepatic differentiation versus profibrogenic potential. Gut. 2008;57:223–31.
Forbes SJ, Russo FP, Rey V, et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology. 2004;126:955–63.
Russo FP, Alison MR, Bigger BW, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology. 2006;130:1807–21.
Baligar P, Mukherjee S, Kochaat V, et al. Molecular and cellular functions distinguish superior therapeutic efficiency of bone marrow CD45 cells over mesenchymal stem cells in liver cirrhosis. Stem Cells. 2016;34:135–47.
Jin ZB, Okamoto S, Mandai M, et al. Induced pluripotent stem cells for retinal degenerative diseases: a new perspective on the challenges. J Genet. 2009;88:417–24.
Carr AJ, Smart MJ, Ramsden CM, et al. Development of human embryonic stem cell therapies for age-related macular degeneration. Trends Neurosci. 2013;36:385–95.
Mummery CL, Zhang J, Ng ES, et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes. Circ Res. 2012;111:344–58.
Lian X, Bao X, Al-Ahmad A, et al. Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling. Stem Cell Rep. 2014;3:804–16.
Imamura T. Differentiation of hepatocytes from mouse embryonic stem cells in three-dimensional culture system imitating in vivo environment. In:Embryonic stem cells – recent advances in pluripotent stem cell-based regenerative medicine: InTech; 2011. p. 291–300. doi:10.5772/14990.
Wernig M, Benninger F, Schmandt T, et al. Functional integration of embryonic stem cell-derived neurons in vivo. J Neurosci. 2004;24:5258–68.
Nsair A, Schenke-Layland K, Handel BV, et al. Characterization and therapeutic potential of induced pluripotent stem cell-derived cardiovascular progenitor cells. PLoS One. 2012;7:e45603.
Song H, Yoon C, Kattman SJ, et al. Interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue. Proc Natl Acad Sci U S A. 2010;107:3329–34.
Naumova AV, Modo M, Moore A, et al. Clinical imaging in regenerative medicine. Nat Biotechnol. 2014;32:804–17.
Chugh AR, Beache GM, Loughran JH, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012;126:S54–64.
Eich T, Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl J Med. 2007;356:2754–5.
Guidance for Industry: Preclinical assessment of investigational cellular and gene therapy products. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm376136.htm.
Guidance for Industry: Potency tests for cellular and gene therapy products. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM243392.pdf.
Thomas RJ, Williams DJ. Large-scale manufacture of therapeutic human stem cells. Pharm Technol. 2009;33:74–9.
Wang H, Sun Z, Wang Y, et al. miR-33-5p, a novel mechano-sensitive microRNA promotes osteoblast differentiation by targeting Hmga2. Sci Rep. 2016;6:23170.
Terraciano V, Hwang N, Moroni L, et al. Differential response of adult and embryonic mesenchymal progenitor cells to mechanical compression in hydrogels. Stem Cells. 2007;25:1730–2738.
Kim DH, Heo SJ, Kang YG, et al. Shear stress and circumferential stretch by pulsatile flow direct vascular endothelial lineage commitment of mesenchymal stem cells in engineered blood vessels. J Mater Sci Mater Med. 2016;27:60.
Kirouac DC, Zandstra PW. The systematic production of cells for cell therapies. Cell Stem Cell. 2008;3:369–81.
Madlambayan GJ, Rogers I, Purpura KA, et al. Clinically relevant expansion of hematopoietic stem cells with conserved function in a single-use, closed-system bioprocess. Biol Blood Marrow Transplant. 2006;12:1020–30.
Boiron JM, Dazey B, Cailliot C, et al. Large-scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity. Transfusion. 2006;46:1934–42.
Olmer R, Haase A, Merkert S, et al. Long term expansion of undifferentiated human iPS and ES cells in suspension culture using a defined medium. Stem Cell Res. 2010;5:51–64.
Storm MP, Orchard CB, Bone HK, et al. Three-dimensional culture systems for the expansion of pluripotent embryonic stem cells. Biotechnol Bioeng. 2010;107:683–95.
Want AJ, Nienow AW, Hewitt CJ, et al. Large-scale expansion and exploitation of pluripotent stem cells for regenerative medicine purposes: beyond the T flask. Regen Med. 2012;7:71–84.
Nienowa AW, Rafiqa QA, Coopmana K, et al. A potentially scalable method for the harvesting of hMSCs from microcarriers. Biochem Eng J. 2014;85:79–88.
Zhao F, Ma T. Perfusion bioreactor system for human mesenchymal stem cell tissue engineering: dynamic cell seeding and construct development. Biotechnol Bioeng. 2005;91:482–93.
Lu B, Malcuit C, Wang S, et al. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells. 2009;27:2126–35.
Heathman TRJ, Nienow AW, McCall MJ, et al. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med. 2015;10:49–64.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Mukhopadhyay, A. (2017). Thriving for the Renewal of Life: Present Needs in Cell Therapy Translational Research. In: Mukhopadhyay, A. (eds) Regenerative Medicine: Laboratory to Clinic. Springer, Singapore. https://doi.org/10.1007/978-981-10-3701-6_20
Download citation
DOI: https://doi.org/10.1007/978-981-10-3701-6_20
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-3700-9
Online ISBN: 978-981-10-3701-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)